Results: Sartorius Stedim Biotech S.A. Exceeded Expectations And The Consensus Has Updated Its Estimates

Sartorius Stedim Biotech S.A. (EPA:DIM) just released its quarterly report and things are looking bullish. The company beat forecasts, with revenue of €745m, some 4.2% above estimates, and statutory earnings per share (EPS) coming in at €0.88, 22% ahead of expectations. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. So we gathered the latest post-earnings forecasts to see what estimates suggest is in store for next year.

Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit.

Following the latest results, Sartorius Stedim Biotech's eleven analysts are now forecasting revenues of €3.00b in 2025. This would be a reasonable 5.1% improvement in revenue compared to the last 12 months. Per-share earnings are expected to soar 61% to €3.39. In the lead-up to this report, the analysts had been modelling revenues of €3.01b and earnings per share (EPS) of €3.14 in 2025. The analysts seems to have become more bullish on the business, judging by their new earnings per share estimates.

See our latest analysis for Sartorius Stedim Biotech

The consensus price target was unchanged at €253, implying that the improved earnings outlook is not expected to have a long term impact on value creation for shareholders. There's another way to think about price targets though, and that's to look at the range of price targets put forward by analysts, because a wide range of estimates could suggest a diverse view on possible outcomes for the business. The most optimistic Sartorius Stedim Biotech analyst has a price target of €310 per share, while the most pessimistic values it at €200. As you can see, analysts are not all in agreement on the stock's future, but the range of estimates is still reasonably narrow, which could suggest that the outcome is not totally unpredictable.

Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry. We would highlight that Sartorius Stedim Biotech's revenue growth is expected to slow, with the forecast 6.9% annualised growth rate until the end of 2025 being well below the historical 8.9% p.a. growth over the last five years. By way of comparison, the other companies in this industry with analyst coverage are forecast to grow their revenue at 11% per year. So it's pretty clear that, while revenue growth is expected to slow down, the wider industry is also expected to grow faster than Sartorius Stedim Biotech.

The Bottom Line

The biggest takeaway for us is the consensus earnings per share upgrade, which suggests a clear improvement in sentiment around Sartorius Stedim Biotech's earnings potential next year. On the plus side, there were no major changes to revenue estimates; although forecasts imply they will perform worse than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.

Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. We have forecasts for Sartorius Stedim Biotech going out to 2027, and you can see them free on our platform here.

It is also worth noting that we have found 1 warning sign for Sartorius Stedim Biotech that you need to take into consideration.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.